Accolade, Inc. (NASDAQ:ACCD) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Accolade, Inc. (NASDAQ:ACCD - Get Free Report) have been given a consensus recommendation of "Hold" by the fourteen ratings firms that are presently covering the firm, Marketbeat.com reports. Thirteen equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $6.51.

ACCD has been the subject of a number of research reports. Needham & Company LLC reissued a "hold" rating on shares of Accolade in a research note on Wednesday, January 8th. Raymond James restated a "market perform" rating on shares of Accolade in a report on Thursday, January 9th. Canaccord Genuity Group reissued a "hold" rating on shares of Accolade in a research report on Wednesday, January 8th. Leerink Partnrs cut shares of Accolade from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, January 8th. Finally, Truist Financial downgraded Accolade from a "strong-buy" rating to a "hold" rating in a research note on Friday, January 10th.

Accolade Stock Up 0.3 %

NASDAQ:ACCD traded up $0.02 during trading hours on Monday, reaching $7.03. The company had a trading volume of 2,285,031 shares, compared to its average volume of 1,412,670. Accolade has a twelve month low of $3.08 and a twelve month high of $9.67. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.67. The firm has a market cap of $576.41 million, a price-to-earnings ratio of -3.12 and a beta of 2.10. The business's 50-day simple moving average is $6.95 and its two-hundred day simple moving average is $5.06.

Accolade (NASDAQ:ACCD - Get Free Report) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, equities analysts expect that Accolade will post -1.2 earnings per share for the current year.

Hedge Funds Weigh In On Accolade

Institutional investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC purchased a new position in Accolade in the fourth quarter worth $48,000. Mackenzie Financial Corp purchased a new position in shares of Accolade in the 4th quarter worth about $456,000. Two Sigma Advisers LP grew its position in Accolade by 322.6% during the fourth quarter. Two Sigma Advisers LP now owns 194,800 shares of the company's stock valued at $666,000 after buying an additional 148,700 shares during the period. Two Sigma Investments LP increased its holdings in Accolade by 302.3% during the fourth quarter. Two Sigma Investments LP now owns 564,743 shares of the company's stock worth $1,931,000 after buying an additional 424,356 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its position in Accolade by 36.8% in the fourth quarter. Point72 Asset Management L.P. now owns 844,999 shares of the company's stock worth $2,890,000 after acquiring an additional 227,420 shares during the period. 84.99% of the stock is owned by institutional investors.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.